SRP-4045: Phase III planned

Sarepta amended its planned double-blind, placebo-controlled Phase III ESSENCE trial to evaluate 30 mg/kg IV SRP-4045 once weekly in patients with deletion mutations amenable to exon 45 skipping and 30 mg/kg IV SRP-4053 once weekly in patients with deletion mutations amenable to

Read the full 424 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE